Literature DB >> 2564552

Warning against use of intrathecal mitoxantrone.

C Hall, W J Dougherty, I J Lebish, P G Brock, A Man.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2564552     DOI： 10.1016/s0140-6736(89)92256-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 2.  Pharmacokinetics and metabolism of mitoxantrone. A review.

Authors:  G Ehninger; U Schuler; B Proksch; K P Zeller; J Blanz
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

3.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.